Target intelligence / Profile preview

Beta-ketoacyl-[acyl carrier protein] synthase (KAS)

Target
KAS
Molecular classification
Enzyme, Acyltransferase, Fatty acid synthase component
01

Overview

Beta-ketoacyl-[acyl carrier protein] synthase is a family of enzymes essential for **fatty acid chain elongation** in the process of fatty acid biosynthesis. The enzyme catalyzes the condensation of an acyl group (commonly acetyl-CoA or propionyl-CoA) with malonyl-ACP, releasing CO₂ and forming a beta-ketoacyl-ACP intermediate, a crucial step in both prokaryotic (Type II) and eukaryotic (Type I) fatty acid synthases[1][2][3]. Multiple isoforms (KAS I, II, III) exist and play distinct roles in the fatty acid chain-length elongation cycle, with KAS III (often designated FabH in bacteria) catalyzing the initial condensation step[2][5]. Beta-ketoacyl-ACP synthase is a validated **antibacterial target**, as inhibition leads to interruption of fatty acid and cell membrane synthesis, incapacitating the pathogen[5][3]. Structural and mechanistic studies show that the active site coordinates a complex set of catalytic residues to enable precise condensation chemistry[1][4]. In plants, multiple isoforms contribute to the biosynthesis of storage and membrane lipids, influencing plant growth, development, and stress responses[4].

Other names
3-Oxoacyl-[acyl-carrier-protein] synthaseBeta-ketoacyl-ACP synthaseKAS (I, II, III)FabH (specifically the III isoform)3-Oxoacyl-ACP synthaseAcetoacetyl-ACP synthase
02

Mechanism of action

Inhibitors block the enzyme's condensation activity, halting fatty acid chain elongation and thereby inhibiting cell membrane synthesis in bacteria

03

Biological functions

Fatty acid biosynthesisCell membrane formationRegulation of cell growth and development (especially in plants)
04

Disease associations

Infection (targeted for antibacterial drug development due to its essential role in bacterial fatty acid synthesis)
05

Safety considerations

Potential toxicity if human homologs (e.g., mitochondrial isoforms) are targeted by broad-spectrum inhibitors. Bacterial specificity is desirable to minimize off-target effects.
06

Interacting drugs

Known inhibitors include several antibacterial agents (e.g., platensimycin, thiolactomycin), though not all are approved drugs. Beta-ketoacyl-ACP synthase is a validated target for novel antibiotics, but specific widely-approved drugs are limited as of 2024
07

Biomarkers

None specific for patient selection; research is ongoing into using fatty acid synthetic enzyme expression as an infection marker.

Beyond the preview

Go deeper on Beta-ketoacyl-[acyl carrier protein] synthase (KAS).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beta-ketoacyl-[acyl carrier protein] synthase (KAS).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call